Skip to main content
Clinical Trials/DRKS00011151
DRKS00011151
Recruiting
Phase 2

Enhancing recovery in early schizophrenia –a multi-center, two-arm, double-blind, randomized clinical trial investigating cannabidiol vs. placebo as an add-on to an individualized antipsychotic treatment

Zentralinstitut für Seelische Gesundheit0 sites180 target enrollmentOctober 7, 2016

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
F20
Sponsor
Zentralinstitut für Seelische Gesundheit
Enrollment
180
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 7, 2016
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Informed consent given by the subject
  • DSM\-IV\-TR diagnosis of schizophrenic psychosis (295\.10, 295\.20, 295\.30, 295\.90\)
  • First documented diagnosis of schizophrenia must not be no older than seven years
  • Patients must receive a stable dose of amisulpride (50 to 1200 mg/day), aripiprazole (10 to 30 mg/day), olanzapine (5 to 20 mg/day), quetiapine (300 to 750 mg/day), or risperidone (1 to 10 mg/day) (TAU: treatment as usual) at least four weeks prior to inclusion in the study to ensure that the maximal effect of the previous medication has been received.
  • Age 18 to 65 years, male or female.
  • Initial PANSS total score of \= 75 at baseline.
  • Female patients of childbearing potential need to utilize a proper method of contraception.
  • Body Mass Index between 18 and 40\.

Exclusion Criteria

  • Lack of accountability (assessed by an independent psychiatrist)
  • Positive urine drug\-screening for illicit drugs at screening (except cannabinoids and benzodiazepines).
  • Serious suicidal risk at screening visit (Subject to investigator’s judgement).
  • Other relevant interferences of axis 1 (e.g. serious depression) according to diagnostic evaluation (MINI) including residual forms of schizophrenia.
  • Other relevant neurological or other medical disorders.
  • Pregnancy, determined through a ß\-HCG pregnancy test, or lactation

Outcomes

Primary Outcomes

Not specified

Similar Trials